Join to View Full Profile
1500 E Medical Center DrAnn Arbor, MI 48109
Phone+1 734-936-4000
Dr. Wilcox is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2011- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2004 - 2007
- Mayo Clinic College of MedicineClass of 2004
Certifications & Licensure
MI State Medical License 2011 - 2027
ID State Medical License 2018 - 2023
MN State Medical License 2005 - 2011
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
- Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas Start of enrollment: 2014 Sep 01
- Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Start of enrollment: 2016 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye, Michael S Khodadoust, Javier Munoz
Leukemia & Lymphoma. 2025-02-08 - 1 citationsThe GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas.Nermin Kady, Suhaib Abdelrahman, Ahmar M Rauf, Alyssa Burgess, Jonathan Weiss
Blood. 2025-02-06 - ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.Amrita Goyal, Daniel O'Leary, Bouthaina Dabaja, Wen-Kai Weng, Jasmine Zain
Transplantation and Cellular Therapy. 2024-11-01
Abstracts/Posters
- A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...Ryan A. Wilcox, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...Ryan A. Wilcox, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Grant Support
- Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomasUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2028
- Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomasUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2028
- Pacritinib in rel/refr T-cell lymphomasUNIVERSITY OF MICHIGAN AT ANN ARBOR2021–2027
- Pacritinib in rel/refr T-cell lymphomasUNIVERSITY OF MICHIGAN AT ANN ARBOR2021–2027
- Pacritinib in rel/refr T-cell lymphomasUNIVERSITY OF MICHIGAN AT ANN ARBOR2021–2027
- Pacritinib in rel/refr T-cell lymphomasUNIVERSITY OF MICHIGAN AT ANN ARBOR2021–2027
- THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESISUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2026
- THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESISUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
